Abstract CT055: PAVO: A phase-II, open label, single arm study of niraparib in patients with locally advanced/metastatic PALB2 mutated tumors
Year: 2023
Type: conference-abstract
Source: Cancer Research
Authors: Tian Zhang, Thomas Weart, Matthias Weiss, Drew Murray, Minaxi Jhawer, Edward Huynh, Shumei Kato, Amy Cummings, Lydia Usha, Arvinder Bhinder, Rajiv Desai, Brad Johnson, Anjali Avadhani, Cecile Rose T. Vibat, Lauren Lopez, Brynna Driscoll, Annajane Ward, Christie K. Rice, Blathnaid Donovan, Scott Sherrin, Mykel Robble, Stephanie O'Leary, Kimberly Blackwell, Amine Aziez, Stephanie Petrone, Kathleen Harnden, Kimberly Strickland, Sonya Reid, Mark Robson, Andrew S. Paulson, Afshin Dowlati
Institutions: The University of Texas Southwestern Medical Center, Virginia Cancer Institute, ThedaCare, Englewood Hospital and Medical Center, Sharp HealthCare, University of California San Diego, University of California, Los Angeles, Rush University Medical Center, OhioHealth, Tempus Labs (United States), GlaxoSmithKline (United States), Inova Health System, Vanderbilt Health, Memorial Sloan Kettering Cancer Center, University Hospitals of Cleveland
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4365512266